

CURRICULUM VITAE

MATTEO SIMONELLI, M.D.

Place and date of birth: Milan, Italy, October 31st, 1979
Citizenship: Italian
Home Address: Via Bassini 31, 20133 Milan, Italy
Office Address: Humanitas University
Department of Biomedical Sciences
Via Rita Levi Montalcini 4, 20090 Pieve Emanuele (Milan), Italy

IRCCS Humanitas Research Hospital
Humanitas Cancer Center - Medical Oncology Unit
Via Manzoni 56, 20089 Rozzano (Milan), Italy

Phone: +39 02 8224 4559 - +39 3485124208
Fax: +39 02 8224 4590
E-mail: matteo.simonelli@hunimed.eu
matteo.simonelli@cancercenter.humanitas.it

Milan Medical License Number: 39503

Very good knowledge of the English language, good knowledge of the French language

CURRENT POSITION

- **Head of Early-phase Drug Development in Solid Tumors**, Medical Oncology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy, Director Professor Armando Santoro.
- **Head of Neuro-Oncology**, Medical Oncology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy, Director Professor Armando Santoro.
- **Assistant Professor in Medical Oncology**, Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4 – 20090 Pieve Emanuele (Milan) Italy.

EDUCATION

- November 3rd, 2008 Medical Oncology Degree, University of Milan, Italy. Thesis entitled: "Tumori del timo: analisi retrospettiva di una casistica monocentrica di 131 pazienti", Supervisor: Prof. Alessandro Massimo Gianni, 70/70 with honors.
- February 2005 Italian Medical License examination; March 1st, 2005 Milan Medical License Number: 39503.
- July 20th, 2004 Medical School Degree, University of Milano-Bicocca, Italy. Thesis entitled: "Concentrazione del DNA cicrolante e alterazioni dei microsatelliti nel DNA tumorale: possibile utilizzo come marcatori nel carcinoma renale", Supervisor: Prof. Roberto Perego, 110/110 with honors.

- July 1998 High School Diploma, Maturità Classica, Liceo Ginnasio Statale "Giosuè Carducci", Milan, Italy.

TRAINING

- 2005 – 2008 Resident in Medical Oncology, Medical Oncology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy, Director Professor Armando Santoro.
- 2002 – 2004 Medical Student in Medical Oncology, Division of Radiation Oncology and Medical Oncology, Ospedale San Gerardo, Monza, Milan, Italy. Director Professor Gianstefano Gardani.

WORK EXPERIENCES

- 2023 – present Head of Early-phase Drug Development in Solid Tumors and Neuro-Oncology, Medical Oncology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy, Director Professor Armando Santoro.
- 2018 – 2022 Lead of Early-phase Drug Development in Solid Tumors, Medical Oncology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy, Director Professor Armando Santoro.
- 2017 – present Assistant Professor in Medical Oncology, Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4 – 20090 Pieve Emanuele (Milan) Italy.
- 2014 – present Lead of Neurooncology, Medical Oncology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy, Director Professor Armando Santoro.
- 2014 – present Consultant (Aiuto) in Medical Oncology, Medical Oncology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy, Director Professor Armando Santoro.
- 2008 – 2013 Assistant in Medical Oncology, Medical Oncology and Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano (Milan), Italy, Director Professor Armando Santoro.

MEMBERSHIPS

1. Member of the Italian Association of Medical Oncology (AIOM)
2. Member of the European Society for Medical Oncology (ESMO)
3. Member of the European Association of Neuro-Oncology (EANO)
4. Member of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
5. Member of the Alliance Against Cancer (ACC)

BOOK CHAPTERS, MANUSCRIPT REVIEWS, PARTICIPATION IN EDITORIAL COMMITTEES

- **Matteo Simonelli**, Pasquale Persico, Angelo Dipasquale, Bruno Bernardini, Marco Riva (2021). Chapter titled: I PAZIENTI LUNGOVIVENTI AFFETTI DA TUMORE CEREBRALE. Clinical

Oncology Manual entitled: "Guariti e Cronici. Manuale di oncologia Clinica" Edisciences Publisher. ISBN 978-88-946075-0-5 2020. p. 395-425.

- **Matteo Simonelli**, Nicolò Battisti, Stefania Boccia, Andrea Poscia (2016). PUBLIC HEALTH & HEALTH POLICY: INNOVAZIONE E SOSTENIBILITÀ IN ONCOLOGIA. Scientific Editor: Walter Ricciardi Full Professor of Hygiene and Public Health at University Cattolica del Sacro Cuore Rome and Past President European Public Health Association. Guest Editor: Armando Santoro, Director of the Humanitas Cancer Center. PUBLIC HEALTH & HEALTH POLICY ANNO III – N. 3 – 2015. ALTIS Omnia Pharma Service S.r.l. 2016.
- **Matteo Simonelli** and Armando Santoro (2015). Editorial titled: Will all cancer patients be treated by targeted therapies in the next 10 years? Patient-centered approaches in oncology: new horizons, MEDICOGRAPHIA, Vol 37, No. 3, 2015
- Ad-hoc reviewer for Reviewer for many Peer-Review Journals (e.g., Cell Reports Medicine; Annals of Oncology)
- September 03rd, 2021 Guest Editor for the peer-review journal *Cancers* (Impact factor 2020: 6,639), Special Issue entitled "*Novel Diagnostic and Therapeutic Approaches in Diffuse Gliomas*"
- Jun 11th, 2019 – Oct 27th, 2019 Abstract Reviewer, XXI AIOM National Congress, Brain Tumors section
- Jun 24th, 2020 – Nov 01st, 2020 Abstract Reviewer, XXII AIOM National Congress, Brain Tumors section
- Jun 16th, 2021 – Oct 24th, 2021 Abstract Reviewer, XXIII AIOM National Congress, Brain Tumors section
- 2019-2022 Member of the AIOM Guidelines Committee for Brain Tumors, 2019 edition; 2020 edition; 2021 edition.

CLINICAL AND TRANSLATIONAL ACTIVITIES

- He had a long-standing interest in the field of clinical and translational cancer research, having been involved in more than 100, national and international, clinical (phase I-II-III) and translational trials according to ICH-GCP, as principal investigator (PI), sub-investigator (SI), or member of the Data Monitoring Committee (DMC).
- Since 2009 he focused his professional activity in early-phase clinical development of anticancer new drugs (molecular targeted agents; immunotherapeutics agents; bispecific antibodies) and Neuroncology

Principal investigator (PI) PROFIT TRIALS:

- **CA012-004**: A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors. Participating Center. Eudract n°: 2015-004816-39.
- **CPDR001I2102**: Phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer. Coordinating Center. Eudract n°: 2017-000466-30.

- **CPDR001X2103:** Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, Ilaris® (canakinumab) or Mekinist® (trametinib). Coordinating Center. Eudract n°: 2016-000633-49.
- **ACT15377:** A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies. Coordinating Center. Eudract n°: 2018-000390-67.
- **CA027-002:** A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers. Participating Center. Eudract n°: 2018-000340-26.
- **BP29889:** An open-label, multicenter, dose escalation phase Ib study with expansion cohorts to evaluate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of ro7009789 (cd40 agonistic monoclonal antibody) in combination with vanucizumab (anti-ang2 and anti-vegf bi-specific monoclonal antibody, part i) or bevacizumab (anti-vegf monoclonal antibody, part ii) in patients with metastatic solid tumors. Participating Center. Eudract n°: 2015-003480-11.
- **CEGF816X2102:** A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC. Participating Center. Eudract n°: 2017-002496-25.
- **1948-CL-0101:** A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumors. Participating Center. Eudract n°: 2018-003873-82.
- **MIN-003-1806:** A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with radiotherapy and temozolomide standard of care treatment. Participating Center. Eudract n°: 2018-000365-37.
- **CC-90010-GBM-002:** A Phase 1b, open-label, dose-finding study of CC-90010 in combination with temozolomide with or without radiation therapy in subjects with newly diagnosed glioblastoma. Coordinating Center. Eudract n°: 2019-004122-25.
- **CA209-76U:** A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab monotherapy and in Combination with Subcutaneous Nivolumab. Participating Center. Eudract n°: 2019-004380-40.
- **AG881-C-004:** A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation. Participating Center. Eudract n°: 2019-002481-13.
- **DZB-CS-202:** A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03). Participating Center. Eudract n°: 2019-004505-27.
- **B26826-101:** Safety, tolerability, efficacy and pharmacokinetic study of increasing doses of b26826 in adult patients with known or suspected brain neoplasms referred for contrast-enhanced MRI of the brain. Coordinating Center. Eudract n°: 2020-003386-20.
- **Sym021-02:** An Exploratory, Open-label, Multicenter Phase 1b Trial to Evaluate Safety and Efficacy of Sym021 (Anti-PD-1) in Combination with Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) in Patients with Advanced Solid Tumor Malignancies. Participating Center. Eudract n°: 2020-002907-20.
- **ARC-9:** A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer. Participating Center. Eudract n°: 2020-005386-13.
- **CO42800:** A phase Ib, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of inavolisib in

- combination with paclitaxel and with or without targeted therapies in patients with locally advanced or metastatic solid tumors. Coordinating Center. [Eudract n°: 2020-005057-24.](#)
- **IDHA-173-001:** A phase 1 study of NMS-03602173 in adult patients with IDH1 and IDH2 mutated solid tumors, including Low Grade Gliomas (LGGs). Participating Center. [Eudract n°: 2021-005489-16.](#)
 - **LCB-1801-001:** A phase I, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers. Participating Center. [Eudract n°: 2021-003808-40.](#)
 - **CA052-002:** A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors. Participating Center. [Eudract n°: 2021-001188-26.](#)
 - **INCB-54828-209:** A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209). Participating Center. [Eudract n°: 2021-004740-24.](#)
 - **MK-1084-001:** A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors. Participating Center. [Eudract n°: 2021-004024-15.](#)
 - **INCB-123667-101:** A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors. Participating Center. [Eudract n°: 2021-005357-91.](#)
 - **CNS-201:** A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy. Participating Center. [Eudract n°: 2021-003659-40.](#)
 - **ITF/3756/01:** A Phase I/Ib, Open-label, Multicentre, Multiple Ascending Doses Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral ITF3756 as Monotherapy and in Combination with an Anti-Cytotoxic T-Lymphocyte-Associated Protein 4 Agent in Patients with Advanced Solid Tumors Participating Center. [Eudract n°: 2022-501089-22-00.](#)
 - **XB002-101:** A dose-escalation and expansion study of the safety and pharmacokinetics of xb002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors. Participating Center. [Eudract n°: 2021-006543-10.](#)
 - **ONC201-108:** ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

Principal investigator (PI) NO PROFIT TRIALS:

- **ONC/OSS-04/2017:** Prospective and comprehensive analysis of circulating and infiltrating leukocyte subsets in patients with diffuse malignant gliomas. Coordinating Center.
- **ONC/OSS-06/2017:** Prospective analysis of cerebrospinal fluid-derived circulating tumour dna as liquid biopsy for management of malignant glioma. Coordinating Center.
- **GBM LTS-2017:** Clinical-neuropathological-molecular study of patients affected by glioblastoma - long survival. Participating Center.
- **EORTC-1635-BTG:** IDH mutated 1p/19q intact lower grade glioma following resection: Wait or Treat? IWOT - A phase III study. Participating Center. [Eudract n°: 2018-003539-31.](#)
- **Gliomi IOV:** Analisi osservazionale retrospettiva per la valutazione dell'outcome nei pazienti affetti da glioma di alto grado. Participating Center.
- **ONC/OSS-06/2020:** Optimizing patient selection for immunotherapeutic early-phase clinical trials: a multicenter experience. Coordinating Center.

- **REGO**: Regorafenib in patients with recurrent glioblastoma (gbm): study of predictive markers and outcome evaluation. Participating Center.
- **IOV-GB-1-2020 REGOMA OSS**: Regorafenib in patients with relapsed glioblastoma. An observational, multicenter, and prospective study. Participating Center.
- **ONC/OSS-01-2021**: Role and predictive potential of distinct circulating and tumor-associated leukocyte subsets in progression and therapeutic response of malignant gliomas and brain metastases from extracranial solid malignancies. Coordinating Center.
- **ONC/OSS-02/2021**: Immune Checkpoint Inhibitor-induced cardiotoxicity: deep phenotypic analysis and strategies for protection. Coordinating Center.
- **IOV-GB-01-2021-REGOMA2**: Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type glioblastoma. A phase I dose-finding study (REGOMA-2). Participating Center. Eudract n°: 2021-001604-15.
- **GLASS-OD**: Glioma longitudinal analysis of 1p-19q codeleted oligodendrogliomas (GLASS-OD). Participating Center.
- **SOPRANO**: studio osservazionale prospettico per l'implementazione della biopsia liquida nel follow-up di pazienti affetti da gliomi e meningiomi di alto grado. Participating Center.

Member of the Data Monitoring Committee (DMC) for the SAR444245 clinical development program, in the following four clinical trials:

1. ACT16849 entitled "A Phase 2 non-randomized, open-label, multi-cohort, multicenter study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with lung cancer or pleural mesothelioma"
2. ACT16902 entitled "A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with advanced and metastatic gastrointestinal cancer"
3. ACT16903 entitled "A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with with other anticancer therapies for the treatment of participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)"
4. ACT16941 entitled "A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) with or without other anticancer therapies for the treatment of adults and adolescents with relapsed or refractory diffuse large B-cell lymphoma"

Member of the Study Steering Committee for:

- The international, multicenter, randomized trial, entitled: **CC-90010-GBM-002**; "A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma". Sponsored by Celgene\ Bristol Myers Squibb
- The early clinical development (First-in-human Trial) of bispecific NK engager **CYt-303** (first-in-class GPC3 Flex-NK™ bispecific antibody) in hepatocellular carcinoma, sponsored by Cytovia Therapeutics, Inc.

RESEARCH GRANTS

- November 29th, 2021 Scientific collaborator (Head of collaboration unit) for the project "Imaging and biological markers for prediction and identification of glioblastoma pseudoprogression: a prospective study". AIRC grant 2021 (AIRC IG ID: 25979, Principal Investigator: Prof. Letterio Politi). Supported by the Italian Association for Cancer Research AIRC: € 580.000.
- 2020-2022 As Clinical Member of Alliance Against Cancer (Brain Tumors Working Group) for the IRCCS Humanitas Research Hospital, was funded for the project entitled "Biopsia Liquida nei Tumori Cerebrali" with € 15.000 in 2020, € 20.000 in 2022.

- November 26th, 2020 Scientific collaborator (Head of collaboration unit) for the project “Immune Checkpoint inhibitor induced cardiotoxicity deep phenotypic analysis and strategies for protection”. AIRC grant 2020 (AIRC IG ID: 24988, Principal Investigator: Prof. Marinos Kallikourdis). Supported by the Italian Association for Cancer Research AIRC: € 566.000.
- 2019 Scientific collaborator (Head of collaboration unit) for the project “Role and predictive potential of distinct circulating and tumor-associated leukocyte subsets in progression and therapeutic response of malignant gliomas “. Bando della Ricerca Finalizzata 2019 (RF-2019-12371549, Principal Investigator: Prof. Locati Massimo). Supported by Italian Ministry of Health: € 450.000
- 2018 Scientific collaborator (Head of collaboration unit) for the project “Depiction of Inflammation in Glioblastoma for prediction and Identification of pseudoprogression and for novel personalized Therapeutic approaches”. 5 x1000 Humanitas Grant 2018 (Principal Investigator: Prof. Politi Letterio). Supported by 5 x1000 Humanitas: € 108.000
- November 23th, 2017 Scientific collaborator (Head of collaboration unit) for the project “Targeting chemokine receptors to harness neutrophil antitumor immune response” AIRC grant 2017 (AIRC IG ID: 20269, Principal Investigator: Prof.ssa Raffaella Bonecchi). Supported by the Italian Association for Cancer Research AIRC: € 450.000.
- 2008 I conceived, designed and wrote the Investigator Sponsored Trial (IST) entitled: “*Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors*”. This trial was approved by the Italian National Health Institute, by the Italian competent authority AIFA and by the local Ethics Committee. This trial was funded in part by GlaxoSmithKline and in part by Bayer Health Care, for a total of **250,000 EUR**, and conducted at the Humanitas Cancer Center between years 2009 and 2010. ClinicalTrials.gov identifier: **NCT00984425**.

INVESTIGATOR SPONSORED TRIAL (IST):

- **Clinical Trials:**
 - Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors”. ClinicalTrials.gov identifier: **NCT00984425**.
- **Translational Studies:**
 - Regulation of the anti-tumor lymphocyte response in patients with metastatic solid tumors treated with the mTOR inhibitor everolimus”. Trial Number: **ONC/OSS-01/2015**.
 - Prospective and comprehensive analysis of circulating and infiltrating leukocyte subsets in patients with diffuse malignant gliomas. Trial Number: **ONC/OSS-04/2017**
 - Prospective analysis of cerebrospinal fluid-derived circulating tumour DNA as liquid biopsy for management of malignant gliomas. Trial Number: **ONC/OSS-06/2017**
 - Optimizing patient selection for immunotherapeutic early-phase clinical trials: a multicenter experience. Trial Number: **ONC/OSS-06/2020**
 - Role and predictive potential of distinct circulating and tumor- associated leukocyte subsets in progression and therapeutic response of malignant gliomas and brain metastases from extracranial solid malignancies. Trial Number: **ONC/OSS-01-2021**
 - Immune Checkpoint Inhibitor-induced cardiotoxicity: deep phenotypic analysis and strategies for protection. Trial Number: **ONC/OSS-02/2021**

ACADEMIC (TEACHING AND ORGANIZATIONAL) ACTIVITIES:

- He is regularly invited to give lectures and provide teaching at national and international courses and preceptorships on early drug development and neuroncology

- 2013 – 2015 Adjunct Professor for students of the International Medical School, University of Milan, Italy
- 2015 – 2017 Adjunct Professor for students of the International Medical School, Humanitas University, Pieve Emanuele (Milan), Italy
- 2016 – 2019 Lecturer at Nursing Degree School of Humanitas University, Pieve Emanuele (Milan), Italy
- July 2019 Member of the Commission for the selection procedure of a research grant (scholarship position), project entitled: “Analisi del sistema immunitario circolante e del microambiente tumorale al basale e dopo chemioterapia neoadiuvante nei pazienti con mesotelioma pleurico maligno (MPM) in stadio iniziale (I-III) candidati a trattamento multimodale” (rif. DR 053/2019), Humanitas University, Pieve Emanuele (Milano)
- December 2019 Member and Designator of the Commission for the selection procedure of a research grant (scholarship position), project entitled: “Analisi estensiva e prospettica di popolazioni leucocitarie infiltranti e circolanti in pazienti affetti da glioma maligno” (rif. DR 121/2019). This position has been funded by Roche SpA. (Liberal donation of € 90.000).
- April 2017 – present Assistant Professor in Medical Oncology, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy.
- April 2017 – present Member of the Faculty of the International Medical School, Humanitas University, Pieve Emanuele (Milan), Italy.
- April 2017 – present Contributed to the conception and drafting of the the integrated course "Oncology and Radiotherapy" (4 credits; 5th year, second semester), as well as to the planning and conducting of the lectures, Humanitas University, Pieve Emanuele (Milan), Italy
- 2017 – present Tutor and Lecturer of Residents in Medical Oncology, for the Residency Program in Medical Oncology, Humanitas University, Pieve Emanuele (Milan), Italy
- 2019 – 2022 Professor in Charge of “Medical Oncology” course, Nursing Degree School of Humanitas University, Pieve Emanuele (Milan), Italy
- 2018 – 2020 Member of the “Commissione Paritetica docenti - studenti”, International Medical School, Nursing Degree School, Physiotherapy Degree School, Humanitas University, Pieve Emanuele (Milan), Italy
- June 18th, 2019. Lecturer, Internship “Radiosurgery and Sterotactic body radiation therapy for solid tumors”: Combined immunotherapy and radiotherapy for melanoma and lung cancer. Humanitas University, Pieve Emanuele (Milan), Italy
- April 2021 Member of the Humanitas University Internal Committee, that actively worked on submitting documents for the Valutazione della Qualità della Ricerca (VQR) 2015-2019, especially for what concerned the “third mission” activities.
- June - August 2021 Expert International Auditor for the evaluation and review process of the Call for Proposal, entitled: "Integrated research action program (PAIR) Brain tumors 2021", of the French National Cancer Institute (INCa).

Doctor of Philosophy (PhD):

- 2019 Clinical Supervisor for The PhD Programme in Molecular and Experimental Medicine (MEM), project title: “Prospective and comprehensive analysis of circulating and infiltrating

leukocyte subsets in patients with diffuse malignant gliomas". Humanitas University, Pieve Emanuele (Milan), Italy.

- October 12th, 2020 Internal Examiner for the candidate Dr.ssa Agnese Losurdo (F7083017) presenting a thesis titled: "Molecular features of T lymphocytes in the immune response against breast cancer ". Open University International PhD Program in Immunology
- May 10th, 2022 Internal Examiner for the candidate Dr.ssa Monica Zuradelli (ID number: 01239) presenting a thesis titled: "DNA repair gene mutations in prostate cancer: a guiding light for enhanced screening and for personalized therapy". PhD in Molecular and Experimental Medicine – XXXIII cycle
- December 17th, 2022 Internal Examiner for the candidate Dr.ssa Milena Mattioli (ID Number: 02410) presenting a thesis titled: "New frontiers of engineered nanovectors to improve treatment efficacy and safety in glioblastoma". PhD in Molecular and Experimental Medicine – XXXV cycle

Lecturer at other Universities:

- February, 2016. Lecturer (Phase I Trials in Elderly Patients), Second level Online Master: Gestione del paziente oncologico complesso - Corso di Alta Formazione: il paziente anziano e la multimorbilità. Unitelma Sapienza University and Accademia Nazionale di Medicina. CME accredited.
- February, 2016. Lecturer (Brain Tumors), Second level Online Master: Gestione del paziente oncologico complesso - Corso di Alta Formazione: il paziente anziano e la multimorbilità. Unitelma Sapienza University and Accademia Nazionale di Medicina. CME accredited.
- May 22nd, 2019. Lecturer, Degree School of Medical and Pharmaceutical Biotechnology, Course of Pharmacological Biotechnology: Immunomodulatory Antibodies in Solid Tumors History and Future Directions. Vita-Salute San Raffaele University, Milan, Italy.
- November 29th, 2018 – December 2nd, 2018. Lecturer (La ricerca in Oncologia Medica), Nursing Master "Case Management in Oncologia", Fondazione IRCCS Policlinico San Matteo, Pavia.
- September 22nd, 2022. Lecturer. "Overview sulla patologia gliale". Master (II° livello) in Farmacia e Farmacologia Oncologica University of Milan. Milan.
- April 26th, 2023. Lecturer. "Development of Anticancer New Drugs: Hurdles and Opportunities". Master (II° livello) in Farmacia e Farmacologia Oncologica University of Milan. Milan.

Supervisor:

School of Medicine:

- Student: Yazeed Fahoum
 - Matr. n. 802056
 - University of Milan, Academic year: 2017-2018
 - Thesis title: "Neutrophil subsets as potential prognostic markers in diffuse malignant gliomas".
- Student: Federico Goncalves Pereira
 - Matr. n. 829758
 - University of Milan, Academic year: 2018-2019
 - Thesis title: "Identifying facility patterns in advanced stage cancer: a call to early palliative care".
- Student: Elisa Paoluzzi Tomada

- Matr. n. 00377
- Humanitas University, Academic year: 2018-2019
- Thesis title: "Characterization of tumor-infiltrating effector regulatory T cells in non-small cell lung cancer"

- Student: Ishwarya Sivakumar
 - Matr. n. 00279
 - Humanitas University, Academic year: 2020-2021
 - Thesis title: "High-grade glioma patients treated into immunotherapeutic early-phase trials: clinical analysis and comprehensive immunophenotyping of circulating leukocytes"

- Student: Sharon Chellakudam
 - Matr. n. 00209
 - Humanitas University, Academic year: 2021-2022
 - Thesis title: "The role of CD8+ and CD4+ T cells in the immune tumor microenvironment of gliomas and brain metastases from extracranial tumors, a retrospective analysis of single cell RNA-sequencing data"

Residency in Medical Oncology:

- Resident: Pasquale Persico
 - Matr. n. 01294
 - Humanitas University, Academic year: 2018-2019
 - Thesis title: "Analisi trascrizionale e fenotipica di cellule mieloidi circolanti ed infiltranti il tumore e correlazione con la prognosi in pazienti affetti da glioma ad alto grado".

Second level Online Master (Gestione del paziente oncologico complesso):

- Student: Silvia Romi
 - Unitelma Sapienza University, Academic year: 2019-2020
 - Thesis title: "Ruolo dei trials clinici di fase I-II nell'applicazione dei farmaci biologici in neuro-oncologia pediatrica".

EDUCATIONAL ACTIVITIES

- Immunoterapie, next step? Evento Wired Health. Milano, March 22nd, 2023.
- "Le nuove sfide nel trattamento dei glioblastomi: oltre le terapie target". Appuntamenti AIOM I mercoledì dell'Oncologia: "Nuove prospettive nel trattamento delle neoplasie cerebrali". Webinar, CME accredited Course. February 8th, 2023.
- Emerging Data for Targeting IL-8, CXCR1, and/or CXCR2 as Potential Treatment Options in Solid Tumors. ESMO Immuno-Oncology Congress 2022 Industry Satellite Symposium. Exploring New Advancements in Chemokine Signaling in Tumor Biology: Focus on IL-8, CXCR1, and CXCR2. Thursday, 8 December 2022, Palexpo, Geneva, Switzerland.
- Tumori cerebrali: inquadramento clinico e opzioni terapeutiche. GSK Training program. November 29th, 2022.
- Le sperimentazioni di fase 1. OPEN MEETING: I Grandi Ospedali Italiani si confrontano con gli stakeholder per fare Sistema. Firenze, Careggi, November 17th-18th, 2022.
- "Inquadramento epidemiologico: di cosa stiamo parlando?" Appuntamenti AIOM: I mercoledì dell'Oncologia: "I meningiomi alla recidiva, una patologia frequente ma spesso trascurata: i nuovi orizzonti". Webinar, CME accredited Course. October 27th, 2021.

- MSI e TMB: un approccio agnostico alla immunoterapia. LANDSCAPES in Oncologia 2021. Precision medicine: “targeted therapy” e immunoterapia. Accademia della Medicina. CME accredited Course. Digital event June 15th, 17th, 21st, 22nd, 2021
- Development of new drugs: hurdles and opportunities. Preceptorship in Lung cancer. Milan, Humanitas University, 12th-13th December 2019.
- La biopsia liquida nei tumori cerebrali primitivi. La biopsia liquida: stato attuale e sviluppi futuri. CME accredited Course. Hotel Michelangelo, Milano, 11th October, 2019.
- Studi di fase I peculiarità. Come si conduce una ricerca clinica. CME accredited Course. Milan, IRCCS Humanitas Research Hospital, 26th September, 2019.
- New Treatment Strategies in Glioblastoma. New Advances in Neurooncology. CME accredited Course. Milano, Humanitas University, 28th-29th June, 2019.
- Le Fasi Cliniche della sperimentazione di un nuovo farmaco. Preceptorship in Immuno-Oncology. Mini Master Immuno-Oncologia. Milan, IRCCS Humanitas Research Hospital, 21st-22nd November, 2017.
- Immunotherapy and Neurooncology: a long way to the top. Neurocenter, Humanitas University. CME accredited Course. Milan, Istituto Clinico Humanitas, 6 Dicembre 2017.
- Immunotherapy in Neurooncology. LANDSCAPES in Immuno-Oncologia, Accademia della Medicina. CME accredited Course. Four Points by Sheraton Milan Center, Milan, 12th-13th October, 2017.
- The Landscape of Immunotherapy in Neurooncology. there is a role for CC-122? Invited Talk, Humanitas Research Day. CME accredited Course. Milan, IRCCS Humanitas Research Hospital, 05th May, 2017.
- Gliomas in the Era of Genomic Medicine. Neurocenter Breakfast Seminar, Humanitas University. CME accredited Course. Milan, IRCCS Humanitas Research Hospital, 21st June, 2016.
- Studi di fase I con anticorpi immunomodulanti. Corso NIBIT di formazione sulla immunoterapia dei tumori umani: basi teoriche, risultati clinici e tossicità delle più promettenti strategie terapeutiche in oncologia. CME accredited Course. Verona, 03rd November, 2015.
- Immunotherapy for Gliomas: Unrealistic Dream or Credible Prospect? Presentazione Orale all'incontro: Neurocenter. CME accredited Course. Istituto Clinico Humanitas - Rozzano (Milano). Rozzano, 16th December, 2014.
- Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose. Grandangolo 2014: Multimorbilità e Cancer Survivors in Oncologia ed Ematologia. CME accredited Course. Milan, 14th-15th April, 2014.
- Targeted Therapy. Lezione al Corso di laurea per infermieri. Istituto Clinico Humanitas - Rozzano (Milan), 30th March, 2011.
- Malattia avanzata e ruolo della chemioterapia ad alte dosi. Presentazione Orale all'incontro: Il Trattamento del tumore del testicolo (in cooperation with the Italian Germ-Cell tumors Group). CME accredited Course. Istituto Clinico Humanitas - Rozzano (Milan), 9th July, 2010.

CLINICAL AND SCIENTIFIC ACTIVITIES

- He has a long-standing qualified experience in research, clinical, and teaching activity in the field of clinical and translational research in oncology and of its applications in clinical diagnostics and treatment of malignant diseases. In particular:
 - From 2004, he has regularly treated patients with solid malignancies in both the inpatient and the outpatient setting.
 - From 2009, he focused his interest on early-phase clinical trials (molecular targeted agents; immunotherapeutics agents) for patients with solid tumors and neurooncology

PUBLICATIONS

- He is Author of more than 80 articles published in peer-reviewed journals, of further articles published in non-peer-reviewed journals, and of book chapters (for book chapters see above)
- He has presented numerous abstracts – including oral presentations - at national and international congresses and conferences
- He is regularly invited as speaker, chairman, discussant, or member of the organizing committee at national and international congresses and conferences

Bibliometric indices according to SCOPUS (March 11th, 2024, ORCID ID: 0000-0002-5264-1251)

Sum of the times cited: 2,335

H-Index: 27

Impact Factor according to Journal Citation Reports, IF 2021

Total Impact Factor: 658,347

ATTACHMENTS


List of publications, participation in congresses and conferences, abstracts

I am aware of the penal sanctions foreseen in case of false declarations as established by art. 76 of law 445/2000.

I hereby grant permission to use my personal data in accordance with GDPR 2016/679.

Milan, 30/08/2024

In Fede, Dott. Matteo Simonelli



ANNEXE n°1: PUBLICATIONS

1. Scirgolea C, Sottile R, De Luca M, Susana A, Carnevale S, Puccio S, Ferrari V, Lise V, Contarini G, Scarpa A, Scamardella E, Feno S, Camisaschi C, De Simone G, Basso G, Giuliano D, Mazza EMC, Gattinoni L, Roychoudhuri R, Voulaz E, Di Mitri D, **Simonelli M**, Losurdo A, Pozzi D, Tsui C, Kallies A, Timo S, Martano G, Barberis E, Manfredi M, Rescigno M, Jaillon S, Lugli E. NaCl enhances CD8+ T cell effector functions in cancer immunotherapy. *Nat Immunol.* 2024 Aug 28. doi: 10.1038/s41590-024-01923-9. Online ahead of print.
2. Dipasquale A, Franceschi E, Giordano L, Maccari M, Barigazzi C, Di Nunno V, Losurdo A, Persico P, Di Muzio A, Navarra P, Pessina F, Padovan M, Santoro A, Lombardi G, **Simonelli M**. Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study. *ESMO Open.* 2024 Jun 3;9(6):103485. doi: 10.1016/j.esmoop.2024.103485. Online ahead of print. PMID: 38833969 Free article.
3. Tropeano MP, Raspagliesi L, Bono BC, Baram A, Rossini Z, Franzini A, Navarra P, Clerici E, Bellu L, **Simonelli M**, Scorsetti M, Riva M, Politi LS, Pessina F. Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification. *Acta Neurochir (Wien).* 2024 Apr 27;166(1):196.
4. Caccese M, Desideri I, Villani V, **Simonelli M**, Buglione M, Chiesa S, Franceschi E, Gaviani P, Stasi I, Caserta C, Brugnara S, Lolli I, Bennicelli E, Bini P, Cuccu AS, Scoccianti S, Padovan M, Gori S, Bonetti A, Giordano P, Pellerino A, Gregucci F, Riva N, Cinieri S, Internò V, Santoni M, Pernice G, Dealis C, Stievano L, Paia F, Magni G, De Salvo GL, Zagonel V, Lombardi G. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma. *ESMO Open.* 2024 Mar 15;9(4):102943. doi: 10.1016/j.esmoop.2024.102943.
5. Di Nunno V, Lombardi G, **Simonelli M**, Minniti G, Mastronuzzi A, Di Ruscio V, Corrà M, Padovan M, Maccari M, Caccese M, Simonetti G, Berlendis A, Farinotti M, Pollo B, Antonelli M, Di Muzio A, Dipasquale A, Asioli S, De Biase D, Tosoni A, Silvani A, Franceschi E. The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study. *J Neurooncol.* 2024 Mar 8. doi: 10.1007/s11060-024-04589-3. Online ahead of print.
6. Miele E, Anghileri E, Calatozzolo C, Lazzarini E, Patrizi S, Ciolfi A, Pedace L, Patanè M, Abballe L, Pattera R, Maddaloni L, Barresi S, Mastronuzzi A, Petrucci A, Tramacere I, Farinotti M, Gurrieri L, Pirola E, Scarpelli M, Lombardi G, Villani V, **Simonelli M**, Merli R, Salmaggi A, Tartaglia M, Silvani A, DiMeco F, Calistri D, Lamperti E, Locatelli F, Indraccolo S, Pollo B. Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study. *Cancer Lett.* 2024 Feb 27:216711. doi: 10.1016/j.canlet.2024.216711. Online ahead of print.
7. Robbrecht D, Grob JJ, Bechter O, **Simonelli M**, Doger B, Borbath I, Butler MO, Cheng T, Romano PM, Pons-Tostivint E, Di Nicola M, Curigliano G, Ryu MH, Rodriguez-Vida A, Schadendorf D, Garralda E, Abbadessa G, Demers B, Amrate A, Wang H, Lee JS, Pomponio R, Wang R. Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors. *Clin Transl Sci.* 2024 Feb;17(2):e13736. doi: 10.1111/cts.13736.
8. Losurdo A[§], Di Muzio A[§], Cianciotti BC, Dipasquale A, Persico P, Barigazzi C, Bono B, Feno S, Pessina F, Santoro A[‡], **Simonelli M[‡]**. T Cell Features in Glioblastoma May Guide Therapeutic Strategies to Overcome Microenvironment Immunosuppression. *Cancers* 2024, 16(3), 603; <https://doi.org/10.3390/cancers16030603>

[‡]These authors share senior authorship.

[§]These authors share first authorship.

9. Bono BC, Ninatti G, Riva M, Raspagliesi L, Barbieri EM, Navarra P, Clerici E, Politi LS, **Simonelli M**, Rodari M, Sollini M, Chiti A, Pessina F. The role of preoperative [11C]methionine PET in defining tumor-related epilepsy and predicting short-term postoperative seizure control in temporal lobe low-grade gliomas. *Neurosurg Focus*. 2024 Feb;56(2):E6. doi: 10.3171/2023.11.FOCUS23678.
10. Losurdo A[§], Dipasquale A[§], Giordano L, Persico P, Lorenzi E, Di Muzio A, Barigazzi C, Korolewicz J, Mehan A, Mohammed O, Scheiner B, Pinato DJ, Santoro A[‡], **Simonelli M[‡]**. Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram. *Front Immunol*. 2024 Jan 15;15:1323151. doi: 10.3389/fimmu.2024.1323151. eCollection 2024.
[‡]These authors share senior authorship.
[§]These authors share first authorship.
11. Dipasquale A, Franceschi E, Lombardi L, **Simonelli M**. Vorasidenib in IDH mutant WHO grade 2 gliomas: time to stop sitting on the fence? *Neuro-Oncol Advanc*, 2024. <https://doi.org/10.1093/noajnl/vdae003>
12. Dipasquale A, Barigazzi C, Losurdo A, Persico P, Di Muzio A, Navarra P, Pessina F, Van den Bent M, Santoro A, **Simonelli M**. Brain metastases and next-generation anticancer therapies: a survival guide for clinicians. *Crit Rev Oncol Hematol*. 2023 Dec 19:104239. doi: 10.1016/j.critrevonc.2023.104239. Online ahead of print.
13. Bosio A, Caffo M, Dipasquale A, Krenqli M, **Simonelli M**, Lombardi G. Editorial: Novel diagnostic and therapeutic strategies in the management of cerebral gliomas, Volume II. *Front Oncol*. 2023 Nov 9;13:1306332. doi: 10.3389/fonc.2023.1306332. eCollection 2023.
14. Carezza C, Franzese F, Castagna A, Terzoli S, **Simonelli M**, Persico P, Bello L, Conti Nibali M, Pessina F, Kunderfranco P, Peano C, Balin S, Mikulak J, Calcaterra F, Bonecchi R, Savino B, Locati M, Della Bella S[‡] and Mavilio D[‡]. Single-cell analysis identifies impaired tumor-infiltrating dendritic cells in patients with newly diagnosed high-grade gliomas. *Front Immunol*. 2023 Jan 10;13:1074762. doi: 10.3389/fimmu.2022.1074762. eCollection 2022. PMID: 36703985
[‡]These authors share senior authorship.
15. Orzan F[§], De Bacco F[§], Lazzarini E[§], Crisafulli G, Gasparini A, Dipasquale A, Barault L, Macagno M, Persico P, Pessina F, Bono B, Giordano G, Zeppa P, Melcarne A, Cassoni P, Garbossa D, Santoro A, Comoglio PM, Indraccolo S, **Simonelli M[‡] and Boccaccio B[‡]**. Liquid biopsy of cerebrospinal fluid enables selective profiling of glioma molecular subtypes at first clinical presentation. *Clin Cancer Res*. 2023 Jan 17: CCR-22-2903. doi: 10.1158/1078-0432.CCR-22-2903. Online ahead of print. PMID: 36648487
[‡]These authors share senior authorship.
[§]These authors share first authorship.
16. Vieito M, **Simonelli M**, de Vos F, Moreno V, Geurts M, Lorenzi E, Macchini M, van den Bent M, Del Conte G, de Jonge M, Martín-Soberón MC, Amoroso B, Sanchez-Perez T, Zuraek M, Hanna B, Aronchik I, Filvaroff E, Chang H, Mendez C, Parro MA, Wei X, Nikolova Z, Sepulveda JM. Trotaresib (CC90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma. *Neurooncol Adv*. 2022 Oct 28;4(1):vdac146. doi: 10.1093/noajnl/vdac146. eCollection 2022 Jan-Dec. PMID: 36382109
17. **Simonelli M**, Garralda E, Eskens F, Gil-Martin M, Yen CJ, Obermannova R, Chao Y, Lonardi S, Melichar B, Moreno V, Yu ML, Bongiovanni A, Calvo E, Rottey S, Machiels JP, Gonzalez-Martin A, Paz-Ares L, Chang CL, Mason W, Lin CC, Reardon DA, Vieito M, Santoro A, Meng R, Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N, Ziti-Ljajic S, Massard C.

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study. *ESMO Open*. 2022 Aug 17;7(5):100562.

18. Caccese M, **Simonelli M**, Villani V, Rizzato S, Ius T, Pasqualetti P, Russo M, Rudà R, Amoroso R, Bellu L, Bertorelle R, Cavallin F, Dipasquale A, Carosi M, Pizzolitto S, Cesselli D, Persico P, Casini B, Fassan M, Zagonel V and Lombardi G. Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDHWild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study. *Cancers* 2022, 14, 2425
19. Santoro A, Su WC, Navarro A, **Simonelli M**, Ch Yang J, Ardizzoni A, Barlesi F, Hyoung Kang J, DiDominick S, Abdelhady A, Chen X, Stammberger U, Felip E. Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer. *Lung Cancer*. 2022 Mar 1;166:170-177. doi: 10.1016/j.lungcan.2022.02.010. Online ahead of print.
20. Persico P, Lorenzi E, Losurdo A, Dipasquale A, Di Muzio A, Navarra P, Pessina F, Politi LS, Lombardi G, Santoro A, **Simonelli M**. Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations. *Cancers (Basel)*. 2022 Feb 22;14(5):1125.
21. Lorenzi E, Morello L, Giordano L, Agostinetto E, Garassino IMG, Cavina R, Mazza R, Persico P, **Simonelli M**, Carlo-Stella C, Santoro A. Quality of life of adult cancer survivors enrolled in Humanitas Research Hospital's survivorship care model. *Support Care Cancer*. 2022 Feb 7. doi: 10.1007/s00520-022-06885-y. Online ahead of print.
22. Navarra P, Pessina F, Clerici E, Bellu L, Franzese C, Franzini A, **Simonelli M**, Bello L, Santoro A, Salvatore Politi L, D'agostino GR, Casarotti A, Fernandes B, Torri V, Scorsetti M. "Re-irradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study. " *Radiother Oncol*. 2021 Dec 21:S0167-8140(21)09067-8. doi: 10.1016/j.radonc.2021.12.019. Online ahead of print.
23. Lombardi G[†], Della Puppa A[†], Pizzi M[†], Cerretti G, Bonaudo C, Gardiman MP, Dipasquale A, Gregucci F, Esposito A, De Bartolo D, Zagonel V, **Simonelli M**[‡], Fiorentino A[‡], Ducray F[‡]. An Overview of Intracranial Ependymomas in Adults. *Cancers (Basel)*. 2021 Dec 5;13(23):6128. doi: 10.3390/cancers13236128.
[†]These authors contributed equally to this work.
[‡]These authors share senior authorship.
24. **Simonelli M**, Persico P[†], Capucetti A[†], Carezza C[†], Franzese S, Lorenzi E, Dipasquale A, Losurdo A, Giordano L, Pessina F, Navarra P, Politi LS, Mavilio D, Locati M, Della Bella S, Santoro A[‡], and Bonecchi R[‡]. Immunotherapeutic early-phase clinical trials and malignant gliomas: a single-center experience and comprehensive immunophenotyping of circulating leukocytes. *Neuro-Oncology Advances*, vdab160, <https://doi.org/10.1093/oaajnl/vdab160> Published:13 November 2021
[†]These authors contributed equally to this work.
[‡]These authors share senior authorship.
25. Cazzetta V, Bruni E, Carezza C, Terzoli S, Piazza R, Cimino M, Donadon M, Torzilli G, **Simonelli M**, Bello L, Villa A, Tan L, Ravens S, Prinz I, Marcenaro E, Supino D, Lugli E, Colombo FS, Della Bella S, Mikulak J and Mavilio D. NKG2A expression identifies a subset of human vδ2 T cells exerting the highest anti-tumor effector-functions. *Cell Rep*. 2021 Oct 19;37(3):109871.
26. Yap TA, Vieito M, Baldini C, Sepúlveda-Sánchez JM, Kondo S, **Simonelli M**, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Löhr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer. *Clin Cancer*

Res. 2021 Sep 21:clincanres.1504.2021. doi: 10.1158/1078-0432.CCR-21-1504. Online ahead of print.

27. Padovan M, Eoli M, Pellerino A, Rizzato R, Caserta C, **Simonelli M**, Michiara M, Caccese C, Anghileri E, Cerretti G, Rudà R, Zagonel V, Lombardi G. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). *Cancers* 2021, 13, 2773. <https://doi.org/10.3390/cancers13112773>.
28. Pessina F, Navarria P, Clerici E, Bellu L, Franzini A, Milani D, **Simonelli M**, Persico P, Politi LS, Casarotti A, Fernandes B, Olei S, Sollini M, Chiti A, Scorsetti M. Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study. *J Clin Med*. 2021 May 25;10(11):2313. doi: 10.3390/jcm10112313.
29. Persico P, Lorenzi E, Dipasquale A, Pessina F, Navarria P, Politi LS, Santoro A, **Simonelli M***. Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives. *J Clin Med*. 2021 Mar 26;10(7):1367. doi: 10.3390/jcm10071367.
*Corresponding author
30. Politi LS, Pessina F, **Simonelli M**, Navarria P. Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging". *J Magn Reson Imaging*. 2021 Mar 12. doi: 10.1002/jmri.27594.
31. Lorenzi E, **Simonelli M**, Persico P, Dipasquale A, Santoro A. Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs. *Expert Opin Drug Saf*. 2021 Feb 18. doi: 10.1080/14740338.2021.1893299. Online ahead of print.
32. Dipasquale A, Persico P, Lorenzi E, Rahal D, Santoro A, **Simonelli M***. COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report. *J Immunother Cancer*. 2021 Feb;9(2):e001870. doi: 10.1136/jitc-2020-001870.
*Corresponding author
33. Reardon DA, Kim TM, Frenel JS, **Simonelli M**, Lopez J, Subramaniam DS, Siu LL, Wang H, Krishnan S, Stein K, Massard C. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. *Cancer*. 2021 Jan 26. doi: 10.1002/cncr.33378. Online ahead of print.
34. **Simonelli M***, Franceschi E, Lombardi G. Neuro-oncology during the COVID-19 outbreak: a hopeful perspective at the end of the Italian crisis. *Front. Med.*, 27 November 2020 <https://doi.org/10.3389/fmed.2020.594610>.
*Corresponding author
35. Pessina F, Navarria P, Bellu L, Clerici E, Politi LS, Tropeano MP, **Simonelli M**, Fornari M, Scorsetti M. Management of glioma patients during the COVID-19 pandemic: what we learned and what we take home for the future. *Neurosurg Focus*. 2020 Dec;49(6):E10. doi: 10.3171/2020.9.FOCUS20704.
36. Muglia R, **Simonelli M**, Pessina F, Morengi E, Navarria P, Persico P, Lorenzi L, Dipasquale A, Grimaldi M, Scorsetti M, Santoro A, Politi LS. Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. *Eur Radiol*. 2020 Nov 17. doi: 10.1007/s00330-020-07471-8.
37. Navarria P, Pessina F, Franzese C, Loi M, Bellu L, Clerici E, Marco Marzo A, **Simonelli M**, Lorenzi E, Salvatore Politi L, Bello L, Fornari M, Rossini Z, Santoro A, Scorsetti M. The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome

evaluation of the two categories in a matched case control study with propensity score balancing. *Radiother Oncol.* 2020 Nov 24;S0167-8140(20)31192-0. doi: 10.1016/j.radonc.2020.11.022. Online ahead of print.

38. **Simonelli M***, Franceschi E, Lombardi G. Neuro-oncology during the COVID-19 outbreak: a hopeful perspective at the end of the Italian crisis. *Front. Med.*, 27 November 2020 <https://doi.org/10.3389/fmed.2020.594610>
*Corresponding author
39. Pessina F, Navarra P, Bellu L, Clerici E, Politi LS, Tropeano MP, **Simonelli M**, Fornari M, Scorsetti M. Management of glioma patients during the COVID-19 pandemic: what we learned and what we take home for the future. *Neurosurg Focus.* 2020 Dec;49(6):E10. doi: 10.3171/2020.9.FOCUS20704.
40. Rossi M, Gay L, Ambrogi F, Nibali MC, Sciortino T, Puglisi G, Leonetti A, Mocellini C, Caroli M, Cordera S, **Simonelli M**, Pessina F, Navarra P, Pace A, Soffietti R, Rudà R, Riva M, Bello L. Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas. *Neuro Oncol.* 2020 Oct 13; noaa225. doi: 10.1093/neuonc/noaa225. Online ahead of print.
41. Caccese M, Ius T, **Simonelli M**, Fassan M, Cesselli D, Dipasquale A, Cavallin F, Padovan M, Salvalaggio A, Gardiman MG, Skrap M, Zagonel V, Lombardi G. Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study. *Int. J. Mol. Sci.* 2020, 21(18), 6716; <https://doi.org/10.3390/ijms21186716>.
42. Navarra P, Pessina F, Clerici E, Rossini Z, Franceschini D, D'Agostino G, Franzese C, Comito T, Loi M, **Simonelli M**, Lorenzi E, Persico P, Politi LS, Grimaldi M, Bello L, Santoro A, Fornari M, Servadei F, Scorsetti M. Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series. *J Neurosurg.* 2020 Sep 4:1-14. doi: 10.3171/2020.5.JNS201116. Online ahead of print. PMID: 32886916
43. Lombardi G, Barresi V, Indraccolo S, Simbolo M, Fassan M, Mandruzzato S, **Simonelli M**, Caccese M, Pizzi M, Fassina A, Padovan M, Masetto E, Gardiman MP, Bonavina MG, Caffo M, Persico P, Chioffi F, Denaro L, Dei Tos AP, Scarpa A, Zagonel V. Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. *Cancers (Basel).* 2020 Aug 14;12(8): E2283. doi: 10.3390/cancers12082283.
44. Dipasquale A, Persico P, Lorenzi E, Bertossi M, Santoro A, and **Simonelli M***. Conducting Phase I trials during the SARS-Cov2 outbreak: about science and care. *Front Oncol.* 22 May 2020. <https://doi.org/10.3389/fonc.2020.00926>.
*Corresponding author
45. D'Alessio A, Personeni N, Pressiani T, Bozzarelli S, Smiroldo V, **Simonelli M**, Lleo A, Santoro A, Rimassa L. COVID-19 and liver cancer clinical trials: not everything is lost. *Liver Int.* 2020 May 20;10.1111/liv.14532. doi: 10.1111/liv.14532. Online ahead of print.
46. **Simonelli M***, Dipasquale A, Orzan F, Lorenzi E, Persico P, Navarra P, Pessina F, Conti Nibali M, Bello L, Santoro A, Boccaccio C. Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients' management: close to the clinic? *Crit Rev Oncol Hematol.* 2020 Feb; 146:102879.
*Corresponding author
47. De Sanctis R, Lorenzi E, Agostinetto E, D'Amico T, **Simonelli M**, Santoro A. Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report. *Medicine (Baltimore).* 2019 Dec;98(50): e18089. doi: 10.1097/MD.00000000000018089.

48. Locarno CV, **Simonelli M**, Carena C, Capucetti A, Stanzani E, Lorenzi E, Persico P, Della Bella S, Passoni L, Mavilio D, Bonecchi R, Locati M, Savino B. Role of myeloid cells in the immunosuppressive microenvironment in gliomas. *Immunobiology*. 2019 Oct 19. pii: S0171-2985(19)30210-4. doi: 10.1016/j.imbio.2019.10.002. [Epub ahead of print] Review.
49. Rossi M, Ambrogi F, Gay L, Gallucci M, Conti Nibali M, Leonetti A, Puglisi G, Sciortino T, Howells H, Riva M, Pessina F, Navarra P, Franzese C, **Simonelli M**, Rudà R, Bello L. Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. *J Neurosurg*. 2019 May 17:1-14. doi: 10.3171/2019.2.JNS183408.
50. Riva M, Lopci E, Castellano A, Olivari L, Gallucci M, Pessina F, Fernandes B, **Simonelli M**, Navarra P, Grimaldi M, Rudà R, Castello A, Rossi M, Alfiero T, Soffietti R, Chiti A, Bello L. Lower grade gliomas: relationships between metabolic and structural imaging with grading and molecular factors. *World Neurosurg*. 2019 Feb 21.
51. Navarra P, Pessina F, Cozzi L, Tomatis S, Reggiori G, **Simonelli M**, Santoro A, Clerici E, Franzese C, Carta G, Conti Nibali M, Bello L, Scorsetti M. Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis. *Tumori*. 2018 Aug 22:300891618792483.
52. Pessina F, Navarra P, Cozzi L, Rudà R, Nibali MC, **Simonelli M**, Costa F, Santoro A, Clerici E, Carta G, Scorsetti M, Bello L. Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment. *Acta Neurochir (Wien)*. 2018 Sep;160(9):1779-1787.
53. **Simonelli M***, Persico P, Perrino M, Zucali PA, Navarra P, Pessina F, Scorsetti M, Bello L, Santoro A. Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top". *Cancer Treat Rev*. 2018 Sep; 69:121-131.
*Corresponding author
54. Navarra P, Pessina F, Franzese C, Tomatis S, Perrino M, Cozzi L, **Simonelli M**, Bello L, Clerici E, Riva M, Santoro A, Scorsetti M. Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. *Radiother Oncol*. 2017 Dec 29.
55. Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, **Simonelli M**, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Laura Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A. Phase II Study of Everolimus in patients with Thymoma and Thymic Carcinoma Previously Treated with Cisplatin-based Chemotherapy. *J Clin Oncol*. 2018 Feb 1;36(4):342-349.
56. Massara M, Persico P, Bonavita O, Mollica Poeta V, Locati M, **Simonelli M** and Bonecchi R. Neutrophils in Gliomas. *Front Immunol*. 2017 Oct 26; 8:1349.
57. Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, **Simonelli M**, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A. Prognostic and predictive role of [18 F] fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. *Cancer Med*. 2017 Oct;6(10):2287-2296.
58. Pessina F, Navarra P, Cozzi L, Tomatis S, Clerici E, Ascolese AM, **Simonelli M**, Perrino M, Riva M, Rossi M, Rudà R, Santoro A, Bello L, Scorsetti M. Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution. *CNS Oncol*. 2017 Jul 18
59. Navarra P, Pessina F, Tomatis S, Soffietti R, Grimaldi M, Lopci E, Chiti A, Leonetti A, Casarotti A, Rossi M, Cozzi L, Ascolese AM, **Simonelli M**, Marcheselli S, Santoro A, Clerici E,

Bello L, Scorsetti M. Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. *Oncotarget*. 2017 Jun 28;8(40):67696-67708.

60. Pessina F, Navarra P, Cozzi L, Ascolese AM, **Simonelli M**, Santoro A, Clerici E, Rossi M, Scorsetti M, Bello L. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. *J Neurooncol*. 2017 Jul 8
61. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EM, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, **Simonelli M**, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. *Ann Oncol*. 2017 May 1;28(5):1036-1041.
62. Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A, Bizzi A, Navarra P, Ascolese AM, Rudà R, Fernandes B, Pessina F, Grimaldi M, **Simonelli M**, Rossi M, Alfieri T, Zucali PA, Scorsetti M, Bello L, Chiti A. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. *Eur J Nucl Med Mol Imaging*. 2017 Jul;44(7):1155-1164.
63. **Simonelli ***, Di Tommaso L, Baretta M, Santoro A. Pathological Characterization of Nivolumab-related Liver Injury in a Patient with Glioblastoma. *Immunotherapy*. 2016 8(12):1363–1369.
*Corresponding author
64. Pessina F, Navarra P, Cozzi L, Tomatis S, Riva M, Ascolese AM, Santoro A, **Simonelli M**, Bello L, Scorsetti M. Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. *J Neurooncol*. 2017 Jan;131(2):377-384.
65. Lorenzi E, **Simonelli M**, Santoro A. Infertility risk and teratogenicity of anticancer molecularly targeted therapy: a challenging issue. *Crit Rev Oncol Hematol*. 2016 Nov; 107:1-13.
66. **Simonelli M***, Zucali P, Santoro A, Thomas MB, De Braud FG, Borghaei H, Berlin J, Denlinger CS, Noberasco C, Rimassa L, Kim TY, English PA, Abbattista A, Gallo Stampino C, Carpentieri M, Williams JA. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase 1 in patients with hepatocellular carcinoma. *Ann Oncol*. 2016 Sep;27(9):1782-7.
*Corresponding author
67. Pessina F, Navarra P, Tomatis S, Cozzi L, **Simonelli M**, Riva M, Santoro A, Ascolese A, Scorsetti M, Bello L. Predictive value of the residual tumor volume after surgical resection in patients with newly diagnosed WHO grade III glioma treated in a multimodal approach: surgery, chemotherapy and radiotherapy. *Ann Surg Oncol*. 2016 Sep;23(9):3040-6.
68. Scorsetti M, Navarra P, Pessina F, Ascolese AM, D'Agostino G, Tomatis S, De Rose F, Villa E, Maggi G, **Simonelli M**, Clerici E, Soffietti R, Santoro A, Cozzi L, Bello L. Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. *BMC Cancer*. 2015 Jun 30; 15:486.
69. **Simonelli M***, Zucali PA, Suter MB, Lorenzi E, Rubino L, Fatuzzo G, Alloisio M, Santoro A. Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports. *Future Oncol*. 2015 Apr;11(8):1223-32.
*Corresponding author
70. Lopci E, Franzese C, Grimaldi M, Zucali PA, Navarra P, **Simonelli M**, Bello L, Scorsetti M, Chiti A. Imaging biomarkers in primary brain tumours. *Eur J Nucl Med Mol Imaging*. 2015 Apr;42(4):597-612.
71. Navarra P, Reggiori G, Pessina F, Ascolese AM, Tomatis S, Mancosu P, Lobefalo F, Clerici E, Lopci E, Bizzi A, Grimaldi M, Chiti A, **Simonelli M**, Santoro A, Bello L, Scorsetti M. Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. *Radiother Oncol*. 2014 Sep;112(3):425-9.

72. Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma WW, **Simonelli M**, Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. *Invest New Drugs*. 2015 Feb;33(1):159-68.
73. Ceresoli GL, Grosso F, Zucali PA, Mencoboni M, Pasello G, Ripa C, Degiovanni D, **Simonelli M**, Bruzzone A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG, Giordano L, Santoro A, Botta M. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. *Br J Cancer*. 2014 Jul 15;111(2):220-6.
74. Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, **Simonelli M**, Gianoncelli L, De Sanctis R, Giordano L, Santoro A. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. *Lung Cancer*. 2014 Jun;84(3):265-70.
75. Rimassa L, Personeni N, **Simonelli M**, Santoro A. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. *Future Oncol*. 2013 Feb;9(2):153-65.
76. Santoro A, **Simonelli M**, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B, Lamar M, Savage RE, Bruix J. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. *Br J Cancer*. 2013 Jan 15;108(1):21-4.
77. Zucali PA, Di Tommaso L, Petrini I, Battista S, Lee HS, Merino M, Lorenzi E, Voulaz E, De Vincenzo F, **Simonelli M**, Roncalli M, Giordano L, Alloisio M, Santoro A, Giaccone G. Reproducibility of the WHO classification of thymomas: practical implications. *Lung Cancer*. 2013 Mar;79(3):236-41.
78. Zucali PA, **Simonelli M**, De Vincenzo F, Lorenzi E, Perrino M, Bertossi M, Finotto R, Naimo S, Balzarini L, Bonifacio C, Timofeeva I, Rossoni G, Mazzola G, Lambiase A, Bordignon C, Santoro A. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours. *Br J Cancer*. 2013 Jan 15;108(1):58-63.
79. **Simonelli M***, Zucali PA, Lorenzi E, Rubino L, De Vincenzo F, De Sanctis R, Perrino M, Mancini L, Di Tommaso L, Rimassa L, Masci G, Zuradelli M, Suter MB, Bertossi M, Fattuzzo G, Giordano L, Roncalli MG, Santoro A. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. *Eur J Cancer*. 2013 Mar;49(5):989-98.
*Corresponding author
80. Scorsetti M, Alongi F, Clerici E, Navarra P, **Simonelli M**, Rognone E, and Santoro A. Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. *Tumori*. 2012 May-Jun;98(3):67e-71e.
81. **Simonelli M***, Rosti G, Banna GL, Pedrazzoli P; on behalf of the Italian Germ cell cancer Group (IGG) and Gruppo Italiano Trapianto Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO). Intensified chemotherapy with stem-cell rescue in germ-cell tumors. *Ann Oncol*. 2012 Apr;23(4):815-22.
*Corresponding author
82. Zucali PA, **Simonelli M**, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M. Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey. *Lung Cancer*. 2012 Mar;75(3):360-7.
83. De Vincenzo F, Zucali PA, Ceresoli GL, Colombo P, **Simonelli M**, Lorenzi E, Perrino M, Gianoncelli L, De Sanctis R, Graziotti P, Santoro A. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma. *J Clin Oncol*. 2011 Jun 20;29(18):e529-31.

84. Zucali PA, Ceresoli GL, De Vincenzo F, **Simonelli M**, Lorenzi E, Gianoncelli L, Santoro A. Advances in the biology of malignant pleural mesothelioma. *Cancer Treat Rev*. 2011 Nov;37(7):543-58.
85. Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, **Simonelli M**, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. *Clin Cancer Res*. 2011 Apr 15;17(8):2581-90.
86. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, **Simonelli M**, Lorenzi E, Ripa C, Giordano L, Santoro A. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. *Lung Cancer*. 2011 Apr;72(1):73-7.
87. **The International Prognostic Factors Study Group**. Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. *J Clin Oncol*. 2010 Nov 20;28(33):4906-11.
88. Zucali PA, Petrini I, Lorenzi E, Merino M, Cao L, Di Tommaso L, Lee HS, Incarbone M, Walter BA, **Simonelli M**, Roncalli M, Santoro A, Giaccone G. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. *Cancer*. 2010 Oct 15;116(20):4686-95.
89. Gaetani P, Hulleman E, Levi D, Quarto M, Scorsetti M, Helins K, **Simonelli M**, Colombo P, Baena y Rodriguez R. Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study. *Tumori*. 2010 Jan-Feb;96(1):97-102.
90. Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, **Simonelli M**, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordinon C. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. *J Clin Oncol*. 2010 May 20;28(15):2604-11.
91. Di Ieva A, Grizzi F, Tschabitscher M, Colombo P, Casali M, **Simonelli M**, Widhalm G, Muzzio PC, Matula C, Chiti A, Rodriguez y Baena R. Correlation of microvascular fractal dimension with positron emission tomography [(11)C]-methionine uptake in glioblastoma multiforme: preliminary findings. *Microvasc Res*. 2010 Sep;80(2):267-73.
92. Zucali PA, De Vincenzo F, **Simonelli M**, Lorenzi E, Perrino M, Santoro A. The role of pemetrexed in the pharmacotherapy of malignant pleural mesothelioma. *Clinical Medicine Insights: Therapeutics*, vol. 2, First Published September 27, 2010.
93. **Simonelli M***, Banna GL, Santoro A. Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy. *Tumori*. 2009 Mar-Apr;95(2):243-7.
*Corresponding author
94. Zucali PA, De Vincenzo F, **Simonelli M**, Santoro A. Future developments in the management of malignant pleural mesothelioma. *Expert Rev Anticancer Ther*. 2009 Apr;9(4):453-67.
95. Banna GL, **Simonelli M**, Santoro A. High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review. *Curr Stem Cell Res Ther*. 2007 Jan;2(1):65-82.
96. Masci G, Magagnoli M, Gullo G, Morenghi E, Garassino I, **Simonelli M**, Santoro A. Herpes infections in breast cancer patients treated with adjuvant chemotherapy. *Oncology*. 2006;71(3-4):164-7.

97. Banna GL, Bettio D, Scorsetti M, Navarria P, **Simonelli M**, Rodriguez Baena R, Aimar E, Gaetani P, Colombo P, Rognone F, Santoro A. Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme. *J Neurooncol*. 2007 Feb;81(3):323-5.

ANNEXE n°2: SCIENTIFIC MEETING PRESENTATIONS

1. **ASCO Annual Meeting 2024 - Poster Session: Central Nervous System Tumors Tumors; abstract n°2065, Poster Bd #: 364.** Enrichment of glioblastoma tumor microenvironment in a GZMK+ T cell population. Losurdo A, Sottile R, Puccio S, Susana A, Dipasquale A, Persico P, Di Muzio A, Bono B, Pessina F, Lugli E, Santoro A, **Simonelli M**. *J Clin Oncol* 42, 2024 (suppl 16; abstr 2065)
2. **ASCO Annual Meeting 2024 - Poster Session: Melanoma/Skin Cancers; abstract n°9597, Poster Bd #: 381.** Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K δ) in patients with uveal melanoma and advanced cancers. Di Giacomo AM, **Simonelli M**, Santangelo F, Amato G, Simonetti E, Graham J, Lahn MF, Di Conza G, Hammett T, Zorrilla R, Durini M, Tan Z, Tadeppally L, Brodin P, Occhipinti M, Carlo-Stella C, Santoro A, Spiliopoulou P, Evans J, Maio M. *J Clin Oncol* 42, 2024 (suppl 16; abstr 9597)
3. **ESMO Immuno-Oncology (IO) 2022 Annual Meeting. Mini Oral Session 2.** Anti-IL-8 BMS-986253 + nivolumab \pm ipilimumab in patients with advanced cancer: update of initial phase 1 results. **Simonelli M[§]**, Calvo C, Davar D, Richards D, Gutierrez M, Moreno V, Marron T, Rottey S, Orcurto A, Renouf D, Joerger M, Barriga Falcon S, Fan J, Gibson E, Chakraborty D, Arora V, Melero I.
[§]Presenter.
4. **SNO 2022 Annual Meeting. Oral Session. Abstract Session: Clinical Trials I. Abstract n° CTIM-03.** Pembrolizumab Monotherapy for Microsatellite Instability-High or Mismatch Repair Deficient Recurrent Gliomas: Results from the Multicohort Phase 2 KEYNOTE-158 Study. Baldini C, Cassier PA, Delord JP, **Simonelli M**, Touat M, Yao L, Duic JP, Gozman A, Marabelle A.
5. **SNO 2022 Annual Meeting. Poster Session. Abstract n° CTNI-21.** Trotabresib (CC-90010) in combination with concomitant temozolomide plus radiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma: updated results from a phase 1b/2 study. Vieito M, Sepulveda JM, Moreno M, de Vos F, Geurts M, Lorenzi L, Macchini M, van den Bent MJ, Del Conte G, Martín-Soberón MC, Brandal P, Martinez Garcia M, Amoroso B, Sanchez-Perez T, Zuraek M, Hanna B, Ellen Filvaroff E, Chang H, Arias Parro M, Wei X, Liu Y, Nikolova Z, **Simonelli M**.
6. **SITC 2022 Annual Meeting. Poster Session, Abstract #707.** A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers. Romano E, Medioni J, De La Motte Rouge T, Fischer N, Bardonneau C, Ferlin W, Hose D, Seckinger A, **Simonelli M**, Curigliano G.
7. **ASCO 2022 Annual Meeting, Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology; abstract n° 3107, poster Bd #99.** First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3K δ)

inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results. Di Giacomo AM, Santangelo F, Amato G, Simonetti E, Graham J, Lahn M, van der Veen LA, Johnson Z, Pickering CA, Durini M, Tan Z, Tadepally L, Brodin P, Occhipinti M, **Simonelli M**, Carlo-Stella C, Santoro A, Spiliopoulou P, Evans J, Maio M.

8. **SABCS 2022 Annual Symposium. Poster Session: MEN1611**, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01). Piccart M, Hennequin A, Borrego MR, Escrivá-de-Romani S, Williams A, Jimenez-Rodriguez J, Del Conte G, Howell SJ, Palleschi M, **Simonelli M**, Duhoux FP, Tosi D, Doger De Speville Uribe B, Jerez Gilarranz Y, Tassone P, Curigliano G, Waters S, Aftimos P, Wildiers H, Scartoni S, Pizà Vallespir B, Shankaraiah RC, Grzegorzewski K, Habboubi N.
9. **AIOM XXIV Congresso Nazionale. Sessione Educazionale: Tumori Cerebrali.** Chair: **Simonelli M**.
10. **EANO 2022 Annual Meeting. Poster Session: P07 Advanced Neurosurgical Techniques, abstract n°p07.08.b.** Surgical management of recurrent lower-grade gliomas: analysis of oncological and functional outcomes and associated factors. Gay L, Rossi M, Sciortino T, Conti Nibali M, **Simonelli M**, Navarra P, Rudà R, Soffietti R, Bello L.
11. **ASCO 2022 Annual Meeting, Poster Session: Developmental Therapeutics—Immunotherapy; abstract n° 2524, poster Bd #180.** Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors. Robbrecht D, Doger B, Grob JJ, Bechter OE, de Miguel MJ, Vieito M, Schadendorf D, Curigliano G, Borbath I, Butler MO, Rodriguez-Vida A, Miller WH, Lin TT, Masson N, Pouzin C, Wang R, Demers B, Amrate A, Abbadessa G, **Simonelli M**
12. **AACR 2022 Annual Meeting. Poster Session: Session PO.CT02.03 - Phase II Trials in Progress. Abstract N° CT119 / 1.** A randomized, double-blind phase 2 evaluation of the anti-IL-8 monoclonal antibody BMS-986253 + nivolumab + ipilimumab vs nivolumab + ipilimumab in patients with advanced melanoma that progressed on/after anti-PD-(L)1 therapy. **Simonelli M** §, Calvo E, Davar D, Melear J, Richards D, Dallos M, Gutierrez M, Moreno V, Marron T, Rottey S, Orcurto A, Barriga S, Fan J, Gibson E, Dutta S, Arora V, Melero I.
§Presenter.
13. **SNO 2021 Annual Meeting. Poster Session: Clinical trials: immunologic; Abstract: CTNI-51.** Adjuvant trotaresib, a reversible potent bromodomain and extraterminal inhibitor (BETi), + temozolomide in newly diagnosed grade 4 glioblastoma: interim results from a phase 1B dose finding study. Vieito M, **Simonelli M**, de Vos F, Moreno V, Geurts M, Lorenzi L, Macchini M, van den Bent M, Del Conte G, de Jonge M, Amoroso B, Sanchez-Perez T, Zuraek M, Hanna B, Aronchik I, Filvaroff E, Mendez C, Wei X, Nikolova N, Sepulveda JM.
14. **AACR 2021 Annual Meeting. Poster Session: Clinical trials; Abstract CT154.** Isatuximab (Isa) Plus Atezolizumab (Atezo) in Patients With Advanced Malignancies: Results From a Phase 1/2 Open-Label Multicenter Study. **Vieito M***, **Simonelli M***, Eskens F, Gil-Martin M, Yen CY, Obermannova R, Chao Y, Zagonel V, Melichar B, Moreno V, Yu MY, Bongiovanni B, Calvo E, Rottey S, Machiels JP, Gonzalez-Martin A, Paz-Ares L, Chang CL, Mason W, Lin CC, Reardon D, Garraida E, Santoro A, Meng R, Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N, Christophe Massard C.
*Equally contributed
15. **ESMO 2021 Annual Meeting. Session: ePoster Display. Abstract 266P.** Phase 1b dose escalation/cohort expansion study of MEN1611, a PI3K Inhibitor, combined with trastuzumab

(T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic breast cancer (ABC). Piccart-Gebhart MJ, Borrego MR, Arkenau HT, Manich CS, Howell S, Hennequin A, Jimenez-Rodriguez B, Del Conte G, **Simonelli M**, Palleschi M, Duhoux FP, Doger B, Curigliano G, Waters S, Aftimos PG, Wildiers H, Tosi D, Amair-Pinedo F, Pellacani AU, Laurent D.

16. **WCLC 2021 Annual Meeting. Poster Presentation. Session: FP14 Targeted therapy - Clinically focused. Abstract n° FP14.08.** Cabozantinib plus atezolizumab in NSCLC patients previously treated with a checkpoint inhibitor: results from COSMIC 021. Neal JW, Lim FL, Felip E, Gentzler R, Patel S, Baranda J, Fang B, Squillante C, **Simonelli M**, Werneke S, Curran D, Ponce Aix S.
17. **XXII AIOM 2020 Annual Meeting. ORAL PRESENTATION. Plenary Session #2.** Final results of depatuxizumab mafodotin (Depatux-m) plus temozolomide (TMZ) in recurrent glioblastoma patients: real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO). Padovan M, Eoli M, Pellerino A, Rizzato S, Caserta C, **Simonelli M**, Michiara M, Caccese M, Anghileri E, Finocchiaro G, Zagonel Z, Rudà R, Lombardi G.
18. **SITC 2020 Annual Meeting. Poster Presentation. Session: In-Progress Clinical Trials, # 394.** Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results. Davar D, **Simonelli M**, Gutierrez M, Calvo E, Melear J, Piha-Pau SA, Richards D, Dallos M, Parameswaran J, Kumar V, Zhao X, Dutta S, Melero I.
19. **ESMO 2020 Annual Meeting. ORAL PRESENTATION. Preferred Paper Session – CNS Tumors. Abstract n°3610.** Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study. Caccese M, **Simonelli M**, Bellu L, Villani V, Rizzato S, Ius T, Pasqualetti P, Russo R, Franchino F, Amoroso R, Bertorelle R, Cavallin F, Dipasquale A, Carosi M, Pizzolitto S, Cesselli D, Gardiman M.P., Padovan M, Zagonel V, Lombardi G.
20. **ESMO 2020 Annual Meeting. Mini Oral – CNS. Abstract n°369MO.** Final results of depatuxizumab mafodotin plus temozolomide in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO) M. Padovan M, Eoli M, Pellerino A, Rizzato S, Caserta C, **Simonelli M**, Michiara M, Caccese M, Anghileri E, Finocchiaro G, Zagonel V, Rudà R, Lombardi G.
21. **ASCO 2020 Annual Meeting. Poster Session – Lung Cancer – Metastatic Non-small Cell Metastatic. Abstract# 9610.** Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. Neal JW, Lim FL, Felip E, Gentzler RD, Patel SB, Baranda J, Fang B, Squillante CM, **Simonelli M**, Werneke S, Curran D, Aix SP.
22. **ASCO 2020 Annual Meeting. Poster Session – CNS Tumors. Abstract# 2539.** Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study. Lombardi G, **Simonelli M**, Bellu L, Villani V, Rizzato S, Ius T, Pasqualetti F, Russo M, Franchino F, Rosina A, Bertorelle R, Cavallin F, Dipasquale A, Carosi M, Pizzolitto S, Cesselli D, Gardiman MP, Caccese M, Padovan M, Zagonel V.
23. **ASCO 2020 Annual Meeting. Poster Session – CNS Tumors. Abstract# 2544.** Depatuxizumab mafodotin (Depatux-M) plus temozolomide (TMZ) in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO). Caccese M, Padovan M, Eoli M, Pellerino A, Rizzato S, Caserta C, **Simonelli M**, Michiara M, Zagonel V, Ruda R, Lombardi L.
24. **XXI AIOM Congresso Nazionale, 25-27 Ottobre 2019, Roma. Educational Session: Tumori Cerebrali. Terapia dei Gliomi Basso Grado. Speaker: **Simonelli M**.**

25. **ESMO 2019 Annual Meeting. Poster Session – Developmental therapeutics. Poster n°492P.** Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): A single phase I Unit experience. **M. Simonelli**, E. Lorenzi, A. Dipasquale, P. Persico, G. Ninatti, L. Giordano, M. Bertossi, A. Santoro.
26. **ESMO 2019 Annual Meeting. Poster Session – CNS Tumors. Poster n°429P.** Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience. **M. Simonelli**, P. Persico, A. Dipasquale, E. Lorenzi, L. Giordano, F. Pessina, P. Navarra, M. Scorsetti, L. Bello, A. Santoro.
27. **ESMO 2019 Annual Meeting. Poster Session – CNS Tumors. Poster n°428P.** Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): An observational study. M. Caccese, **M. Simonelli**, M. Fassan, M. Padovan, P. Persico, L. Bellu, A. Dipasquale, M.P. Gardiman, S. Indraccolo, V. Zagonel, G. Lombardi.
28. **EANO 2019 Annual Meeting. Poster Session – Early clinical trials. Poster n°P05.08.** High-grade gliomas and immunotherapeutic early phase clinical trials: a single-center experience. **M. Simonelli**, P. Persico, A. Dipasquale, E. Lorenzi, L. Giordano, F. Pessina, P. Navarra, M. Scorsetti, L. Bello, A. Santoro.
29. **EANO 2019 Annual Meeting. ORAL PRESENTATION – Abstract n°P2.2.** Pembrolizumab (pem) in recurrent high-grade glioma (hgg)patients with mismatch repair deficiency (dmmr): an observational study. M. Caccese, **M. Simonelli**, M. Fassan, M. Padovan, P. Persico, L. Bellu, A. Dipasquale, M. Gardiman, S. Indraccolo, V. Zagonel, G. Lombardi.
30. **ASCO GI 2019 Meeting. Poster Session - CANCERS OF THE PANCREAS, SMALL BOWEL, AND HEPATOBILIARY TRACT. Poster n°406.** Prognostic factors and disease course in patients enrolled onto clinical trials of second-line therapy for hepatocellular carcinoma. N. Personeni, T. Pressiani, A. D'Alessio, M.G. Prete, S. Bozzarelli, V. Smiroldo, **M. Simonelli**, L. Giordano, A.Santoro, L. Rimassa. Journal of Clinical Oncology37, no. 4_suppl (February 1 2019) 406-406.
31. **AIOM XX Congresso Nazionale, 16-18 Novembre 2018, Roma. Educational Session: Tumori Cerebrali.** Chair: **Simonelli M.**
32. **ESMO 2018 Meeting. ORAL PRESENTATION. Proffered Paper session - CNS tumours. Poster n°374O.** Mismatch repair deficiency (MMRd) in glioma patients (PTS): Frequency and correlation with clinical, histological and molecular characteristics. G. Lombardi, M. Caccese, **M. Simonelli**, M. Fassan, P. Persico, E. Lorenzi, R. Bertorelle, M.P. Gardiman, L. Bellu, A. Pambuku, A. Santoro, V. Zagonel
33. **ESMO 2018 Meeting. Poster display session - Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research. Poster n°1392P.** Dose-determination results from a phase Ib/II study of ceritinib (CER) 1 ribociclib (RIB) in ALK-positive (ALK1) non-small cell lung cancer (NSCLC) A. Santoro, W-C. Su, A. Navarro, **M. Simonelli**, J.C-H. Yang, A. Ardizzoni, F. Barlesi, J.H. Kang, S. Didominick, A. Abdelhady, B. Goswami, A. Crystal, E. Felip
34. **EANO 2018 Meeting. Glioma - Clinical Aspects. Poster n°P01.043.** Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment. F. Pessina, P. Navarra, M. Conti Nibali, M. Riva, G. Carta, E. Clerici, **M. Simonelli**, R. Rudà, M. Scorsetti, L. Bello.
35. **EANO 2018 Meeting. Glioma - Preclinical Aspects. Poster n°P04.86.** Correlation between activated infiltrating neutrophils and MGMT methylation in patients with diffuse malignant

gliomas (MGs). **M. Simonelli**, M. Massara, P. Persico, A. Capucetti, E. Lorenzi, E. Lugli, A. Dipasquale, M. Nibali, M. Rossi, L. Bello, M. Locati, R. Bonecchi.

36. **EANO 2018 Meeting. Glioma - Clinical Aspects. Poster n°P01.073.** Hypofractionated radiation therapy (over 3 weeks) can replace conventional radiation therapy schedule (over 6 weeks) in newly diagnosed glioblastoma patients? The times are ripe. P. Navarra, E. Clerici, F. Pessina, C. Franzese, L. Bello, **M. Simonelli**, S. Tomatis, A. Leonetti, M. Scorsetti.
37. **EANO 2018 Meeting. Glioma - Clinical Aspects. Poster n°P01.018.** Mismatch repair deficiency (MMRd) in glioma patients (PTS): frequency and correlation with clinical, histological and molecular characteristics. G. Lombardi, M. Caccese, **M. Simonelli**, M. Fassan, P. Persico, E. Lorenzi, R. Bertorelle, M. Gardiman, L. Bellu, A. Pambuku, A. Santoro, V. Zagonel.
38. **ASCO 2018 Meeting. Poster Session - Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Thymic Malignancies. Poster n°8579.** A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy. M. Perrino, S. Bozzarelli, P.A. Zucali, T.M. De Pas, **M. Simonelli**, F. De Vincenzo, F. Conforti, P. Persico, C. Miggiano, N. Cordua, A. Cioffi, S.Sala, F.Mrakic Sposta, L. Giordano, A. Santoro.
39. **2016 SNO Annual Meeting. ORAL PRESENTATION. Session 3A Clinical Trials – II.** A phase 1a/1b, multicenter, open label dose finding study to assess the safety, tolerability and efficacy of the pleiotropic pathway modifier CC122 administered orally to patients with glioblastoma multiforme (GBM) and other brain tumors. **M. Simonelli**, J. Sepulveda, A. Brandes, J.C. Soria, J. Edenfield, V. Moreno, J. Gallego Pérez Larraya, C. Britten, T.F. Cloughesy, M. Martinez Garcia, C. Balana, P. Hagner, Y. Li, X. Wei, A. Gandhi, M. Pourdehnad, J. A. Lopez Martin, A. Santoro, K. Shih. **Presenter: M. Simonelli.**
40. **2016 EANO Annual Meeting. Poster Session, Glioblastoma and Anaplastic Gliomas.** Poster N.: P028.28. Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation. F. Pessina, P. Navarra, A. Ascolese, L. Cozzi, S. Tomatis, M. Riva, **M. Simonelli**, M. Scorsetti, L. Bello.
41. **2016 EANO Annual Meeting. Poster Session, Glioblastoma and Anaplastic Gliomas.** Poster N.: P028.44. Phase II study of hypofractionated radiation therapy with concomitant and adjuvant temozolomide following surgical resection for patients with newly diagnosed glioblastoma: preliminary evaluation. P. Navarra, F. Pessina, A. Ascolese, S. Tomatis, L. Bello, **M. Simonelli**, A. Santoro, M. Scorsetti,.
42. **2015 ECCO/ESMO Annual Meeting. Proffered Paper Session, Immunotherapy in Cancer II,** Abstract No: 500. Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. P.A. Ott, S.A. Piha-Paul, P. Munster, M.J. Pishvaian, E. Van Brummelen, R. Cohen, C. Gomez-Roca, S. Ejadi, M. Stein, E. Chan, **M. Simonelli**, A. Morosky, S.S. Yuan, M. Koshiji, J. Bennouna.
43. **2015 ASCO Annual Meeting. Poster Session, Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics** Abstract No: 2549. Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma. P. Zucali, **M. Simonelli**, F. De Vincenzo, G. Fatuzzo, M. Bertossi, M. Perrino, C. Miggiano, L. Giordano, C. Bonifacio, F. Mrakic Sposta, A. Santoro; Humanitas Cancer Center, Rozzano, Italy. J Clin Oncol 33, 2015 (suppl; abstr 2549).
44. **2015 WCLC Annual Meeting. Poster Session Thymoma, Mesothelioma and Other Thoracic Malignancies.** Poster Board Number: P2.08-005. Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (mpm) patients. GL. Ceresoli, PA .Zucali, F. Grosso, M. Mencoboni, HS. Soto Parra, G. Pasello, D. Cortinovis, M. Bonomi, M.

Perrino, A. Muzio, A. Bruzzone, F. De Vincenzo, D. Degiovanni, **M. Simonelli**, GD. Beretta, L. Giordano, A. Santoro. *Denver, September 6 - 9, 2015.*

45. **2014 ENA AACR/NCI/EORTC Annual Meeting (Symposium on Molecular Targets and Cancer Therapeutics).** Poster Session Molecular Targeted Agents II. Poster Board Number: P114. Tivantinib in combination with gemcitabine shows strong antitumor activity on mesothelioma cell lines and cytoskeletal effects via inhibition of actin. **M. Simonelli**, P.A. Zucali, M.B. Suter, L. Rubino, A. Santoro. *Barcelona, November 18 - 21, 2014. European Journal of Cancer, Vol. 50, p176.*
46. **2014 IMIG Meeting.** Poster Session 2, Poster Presentation. Poster Board Number: P2.053. Phase I-Ib trial of Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients (pts) with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma (MPM). P. Zucali, **M. Simonelli**, F. De Vincenzo, M. Perrino, G. Fatuzzo, M. Bertossi, L. Giordano, M. Suter, M. Gemelli, F. Mrakic Sposta, A. Santoro.
47. **2014 IMIG Meeting.** Poster Session 2, Poster Presentation. Poster Board Number: P2.060. Double-blind placebo-controlled randomized phase 2 trial of NGR-hTNF as switch maintenance treatment after completion of first-line chemotherapy in mesothelioma. P. Zucali, M. Botta, F. Grosso, M. Mencoboni, C. Porta, A. Favaretto, F. Grossi, G. Rosti, C. Dazzi, F. De Vincenzo, **M. Simonelli**, M. Perrino, A. Lambiase, C. Bordignon, A. Santoro.
48. **2014 IMIG Meeting.** Poster Session 1, Poster Discussion. Poster Board Number: P1.07. Role of baseline and interim fluorodeoxyglucose positron emission tomography (FDG-PET) evaluation for response assessment and outcome definition in malignant pleural mesothelioma (MPM) patients not receiving talc pleurodesis. P. Zucali, E. Lopci, G. Ceresoli, M. Perrino, L. Giordano, L. Gianoncelli, E. Lorenzi, M. Gemelli, G. Ciocia, **M. Simonelli**, F. De Vincenzo, C. Bonifacio, L. Setti, A. Chiti, A. Santoro.
49. **2014 IMIG Meeting.** Poster Session 1, Poster Presentation. Poster Board Number: P1.033. Role of proton-coupled folate transporter expression in resistance of mesothelioma patients treated with pemetrexed. P. Zucali, E. Giovannetti, M. Perrino, Y. Assaraf, M. Gemelli, N. Funel, M. Stark, L. Leon, F. De Vincenzo, Z. Hou, **M. Simonelli**, L. Matherly, M. Suter, G. Peters, A. Santoro.
50. **2014 ASCO Annual Meeting.** General Poster Session, Gastrointestinal (Noncolorectal) Cancer Abstract No: 4095. Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control. **Presenting Author: Matteo Simonelli**, Humanitas Cancer Center, Rozzano, Italy. *J Clin Oncol 32:5s, 2014 (suppl; abstr 4095)*
51. **2014 ASCO Annual Meeting.** General Poster Session, Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Abstract No: TPS7610. Phase I-Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesothelioma (MPM). P. Zucali, **M. Simonelli**, F. De Vincenzo, G. Fatuzzo, M. Bertossi, M. Suter, M. Perrino, L. Giordano, A. Santoro; Humanitas Cancer Center, Rozzano, Italy. *J Clin Oncol 32:5s, 2014 (suppl; abstr TPS7610).*
52. **2014 ASCO Annual Meeting.** Poster Highlights Session, Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers Abstract No: 7527. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. P. Zucali, T.M. De Pas, G. Palmieri, A. G. Favaretto, A. Chella, M. Tiseo, M. Caruso, M. Perrino, F. De Vincenzo, **M. Simonelli**, F. Toffalorio, P. Federico, G. Pasello, M. Ali, L. Giordano, M. Bertossi, A. Santoro. *J Clin Oncol 32:5s, 2014 (suppl; abstr 7527)*
53. **2013 ASCO Annual Meeting.** General Poster Session, Gastrointestinal (Non colorectal) Cancer (Board #28B) Abstract No: 4121. Phase I study of PF-03446962 (anti-ALK-1 mAb) in

hepatocellular carcinoma (HCC). **Presenting Author: Matteo Simonelli**, Humanitas Cancer Center, Rozzano, Italy. J Clin Oncol 31, 2013 (suppl; abstr 4121).

54. **2012 ASCO Annual Meeting. General Poster Session (Board #6E)** Abstract No: 4117. Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGRhTNF given at high doses in patients with refractory solid tumors. P. Zucali, **M. Simonelli**, F. De Vincenzo, E. Lorenzi, M. Perrino, M. Bertossi, L. Balzarini, C. Bonifacio, A. Lambiase, C. Bordignon, A. Santoro.
55. **2012 ASCO Annual Meeting. General Poster Session (Board #50D)** Abstract No: 2580. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. Martell, I. Puzanov, W. Wee Ma, A. Santoro, G.K. Dy, L. Goff, G. Fetterly, Shaunita A. Michael, Julie Ann Means-Powell, F. Chai, M. Lamar, **M. Simonelli**, W. Chiang, J. Jarboe, B. Schwartz, AA. Adjei
56. **2011 ESMO/ECCO Annual Meeting. Oral Presentation.** Abstract No: 1205. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors. P. A. Zucali, A. Santoro, **M. Simonelli**, F. De Vincenzo, E. Lorenzi, L. Rimassa, L. Balzarini, V. Quagliuolo, A. Lambiase, C. Bordignon. **Presenter: M. Simonelli**
57. **2011 ESMO/ECCO Annual Meeting. General Poster Session.** Abstract No: 1247 Phase I, pharmacokinetics (PK), pharmacodynamic (PD) study of Lapatinib (L) in combination with Sorafenib (S) in patients with advanced refractory solid tumors. **M. Simonelli**, P.A. Zucali, R. De Sanctis, E. Lorenzi, F. De Vincenzo, L. Rimassa, M.C. Tronconi, M. Zuradelli, L. Giordano, A. Santoro.
58. **2011 ASCO Annual Meeting. Poster Discussion.** Abstract No: 82026. Phase I, pharmacokinetics (PK), pharmacodynamic (PD) study of Lapatinib (L) in combination with Sorafenib (S) in patients with advanced refractory solid tumors. **M. Simonelli**, P.A. Zucali, R. De Sanctis, E. Lorenzi, F. De Vincenzo, L. Rimassa, M.C. Tronconi, N. Personeni, G. Masci, M. Zuradelli, L. Giordano, A. Santoro.
59. **2011 ASCO Annual Meeting. Poster Discussion.** Abstract No: 82039. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors. P. A. Zucali, **M. Simonelli**, F. De Vincenzo, E. Lorenzi, L. Rimassa, L. Balzarini, V. Quagliuolo, A. Lambiase, C. Bordignon, A. Santoro.
60. **2011 ASCO Annual Meeting. General Poster Session.** Abstract No: 81969. NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM). F. De Vincenzo, G. Rossoni, A. Santoro, V. Gregorc, P. A. Zucali, G. Citterio, **M. Simonelli**, G. Petrella, F. Caligaris-Cappio, A. Lambiase, C.
62. **2010 ASCO Annual Meeting. General Poster Session, Gastrointestinal (Noncolorectal) Cancer Abstract.** Abstract No: 4137. Final results from ARQ 197-114: A phase Ib safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC). P. Zucali, A. Santoro, C. Rodriguez-Lope, **M. Simonelli**, L. H. Camacho, N. N. Senzer, L. Bolondi, M. Lamar, G. Abbadessa, B. E. Schwartz. J Clin Oncol 28:15s, 2010 (suppl; abstr 4137).
63. **2010 ASCO Annual Meeting. Published in conjunction with the meeting.** Abstract No: e13091. Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors. **M. Simonelli**, A. Santoro, P. A. Zucali, L. Rimassa, F. De Vincenzo, T. Pressiani, M. C. Tronconi, C. Carnaghi, A. Lambiase, C. Bordignon. J Clin Oncol 28, 2010 (suppl; abstr e13091).
64. **2010 ASCO Annual Meeting. General Poster Session, Lung Cancer - Local-Regional and Adjuvant Therapy.** Abstract No: 7041. Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM). E. Lorenzi, L. Gianoncelli, P. Zucali, G. Ceresoli,

F. De Vincenzo, **M. Simonelli**, C. Ripa, L. Giordano, A. Santoro. J Clin Oncol 28:15s, 2010 (suppl; abstr 7041).

65. **2010 ASCO Annual Meeting.** Published in conjunction with the meeting. Abstract No: e18106. Retreatment with pemetrexed-based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM): An observational study. F. De Vincenzo, P. Zucali, G. Ceresoli, L. Gianoncelli, E. Lorenzi, **M. Simonelli**, C. Ripa, L. Giordano, A. Santoro. J Clin Oncol 28, 2010 (suppl; abstr e18106).
66. **2010 ASCO Gastrointestinal Cancers Symposium.** General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract. Abstract No: 187. A phase Ib safety trial of ARQ 197 in cirrhotic patients with hepatocellular carcinoma (HCC). A. Santoro, **M. Simonelli**, P. Zucali, L. Rimassa, N. N. Senzer, L. H. Camacho, L. Bolondi, M. Lamar, G. Abbadessa, J. Bruix.
67. **2010 ESMO Annual Meeting.** Poster presentation. Biomarker results from ARQ 197-114: a phase Ib trial evaluating the c-met inhibitor ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC). **M. Simonelli**, C. Rodriguez-Lope, L. Rimassa, L. Bolondi, L. H. Camacho, N. Senzer, G. Abbadessa, C. Waghorne, A. Santoro, J. Bruix.
68. **2010 ESMO Annual Meeting.** Poster Presentation. Phase I and pharmacodynamic study of NGR-hTNF at high doses in refractory patients with solid tumors. P.A. Zucali, A. Santoro, **M. Simonelli**, F. De Vincenzo, E. Lorenzi, L. Rimassa, L. Balzarini, V. Quagliuolo, A. Lambiase, C. Bordinon. Annals of Oncology 2010, vol 21 (Supplement 8): viii162-viii184.
69. **2010 ESMO Annual Meeting.** Poster Presentation. Vinorelbine (V) in pemetrexed-pretreated patients (Pts) with malignant pleural mesothelioma (MPM). F. De Vincenzo, E. Lorenzi, P.A. Zucali, **M. Simonelli**, L. Gianoncelli, G.L. Ceresoli, C. Ripa, L. Giordano, A. Santoro. Annals of Oncology 2010, vol 21 (Supplement 8): viii122-viii161.
70. **2010 IMIG Meeting.** Oral presentation. Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM). Zucali PA, Lorenzi E, Ceresoli GL, De Vincenzo F, Gianoncelli L, **Simonelli M**, Ripa C, Giordano L, Santoro A. *International Mesothelioma Interest Group (IMIG)*, Settembre 2010, Kyoto.
71. **2010 IMIG Meeting.** Oral presentation. Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma (MPM). Ceresoli GL, Zucali PA, Mencoboni M, De Vincenzo F, Botta M, Grossi F, Bidoli P, Bajetta E, Ardizzoni A, Favaretto A, **Simonelli M**, Lorenzi E, Gianoncelli L, Chiti A, Santoro A. *International Mesothelioma Interest Group (IMIG)*, Settembre 2010, Kyoto.
72. **2010 IMIG Meeting.** Oral presentation. Retreatment with pemetrexed based chemotherapy (PBC) in patients with malignant pleural mesothelioma. (MPM). Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, **Simonelli M**, Lorenzi E, Ripa C, Giordano L, Santoro A. *International Mesothelioma Interest Group (IMIG)*, Settembre 2010, Kyoto.
73. **2010 IMIG Meeting.** Oral presentation. Thymidylate synthase and excision repair cross-complementing group 1 as predictors of responsiveness in patients with malignant pleural mesothelioma treated with pemetrexed and carboplatin. Zucali PA, Destro A, Giovannetti E, Ceresoli GL, Mencoboni M, Gianoncelli L, Lorenzi E, De Vincenzo F, **Simonelli M**, Thunninsen E, Perrino M, Giordano L, Peters G, Roncalli M, Santoro A. *International Mesothelioma Interest Group (IMIG)*, Settembre 2010, Kyoto.
74. **2010 IMIG Meeting.** Oral presentation. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter study. Zucali PA, **Simonelli M**, Michetti G, Ceresoli GL, Tiseo M, Collova E, Follador A, De Vincenzo F, Lorenzi E, Perrino M, Gianoncelli L, Giordano L, Santoro A, Garassino M. *International Mesothelioma Interest Group (IMIG)*, Settembre 2010, Kyoto.

75. **2010 AIOM Annual Meeting. Poster Presentation.** Thymidylate synthase expression and outcome in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin. Zucali PA, , Giovannetti E, Ceresoli GL, Mencoboni M, Destro A Gianoncelli L, Lorenzi E, De Vincenzo F, **Simonelli M**, Perrino M, Giordano L, Roncalli M, Santoro A.
76. **2010 AIOM Annual Meeting. Poster Presentation.** Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma (MPM). Ceresoli GL, Zucali PA, De Vincenzo F, Mencoboni M, Botta M, Grossi F, Bidoli P, Bajetta E, Ardizzoni A, Favaretto A, **Simonelli M**, Lorenzi E, Gianoncelli L, Chiti A, Santoro A.
77. **2010 AIOM Annual Meeting. Poster Presentation.** Retreatment with pemetrexed based chemotherapy in patients with malignant pleural mesothelioma. De Vincenzo F Ceresoli GL, Zucali PA, , Gianoncelli L, **Simonelli M**, Lorenzi E, Ripa C, Giordano L, Santoro A.
78. **2010 AIOM Annual Meeting. Poster Presentation.** Vinorelbine (V) in pemetrexed-pretreated patients with malignant pleural mesothelioma (MPM). **Simonelli M**, Lorenzi E, Zucali PA, Ceresoli GL, De Vincenzo F, Gianoncelli L, Ripa C, Giordano L, Santoro A.
79. **2009 ASCO Annual Meeting. Published in conjunction with the meeting.** Abstract No: e13037. Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas. **M. Simonelli**, G. Banna, P. Navarra, A. Di Ieva, P. Zucali, F. De Vincenzo, P. Gaetani, R. Condorelli, R. Rodriguez y Baena, M. Scorsetti, A. Santoro; Istituto Clinico Humanitas, Rozzano, Italy; Vittorio Emanuele University Hospital, Catania, Italy. J Clin Oncol 27, 2009 (suppl; abstr e13037).
80. **2009 ESMO Annual Meeting. Poster Presentation.** Abstract No: P-9127. The role of thymidylate synthase (TS) and excision repair cross-complementing group 1 (ERCC1) immunohistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin. P. Zucali, A. Destro, G.L. Ceresoli, L. Gianoncelli, E. Lorenzi, F. De Vincenzo, **M. Simonelli**, L. Giordano, M. Roncalli, A. Santoro. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 543.
81. **2008 AINO XIII Congresso della Società italiana di Neuro oncologia**, Roma 29 giugno -2 Luglio 2008. Oral Comunicazione. Associazione della Temozolomide alla radioterapia per il trattamento dei gliomi anaplastici di nuova diagnosi. Presenter: **M. Simonelli**.
82. **2008 IMIG Meeting. Poster Presentation.** Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma (MPM). Ceresoli GL, Zucali PA, De Vincenzo F, Mencoboni M, Grossi F, **Simonelli M**, Timofeeva I, Chiti A, Santoro A.
83. **2008 IMIG Meeting. Poster Presentation.** Re-treatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma (MPM): an observational study. F. De Vincenzo, P.A. Zucali, G. L. Ceresoli, **M.Simonelli**, L.Gianoncelli, E. Lorenzi, A. Santoro.
84. **2006 ESMO Annual Meeting. Poster Presentation.** Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy. G.L. Banna, G. Gullo, G. Masci, **M. Simonelli**, L. Rimassa, L. Di Tommaso, D. Bettio, M. Roncalli , A. Santoro. Annals of Oncology 2006, vol 17 (Supplement 9): ix93–ix113.
85. **2006 AIOM Annual Meeting. Poster presentation.** Optimizing residual surgery for patients with primary extragonadal germ cell tumors. **Simonelli M**, Banna G, De Giorgi U, Ferrari B, Alloisio M, Incarbone M, Chiti A, Rosti G & Santoro A. Annals of Oncology, 2006, Vol 17, suppl 11, xi75–xi83, Abs L6.

